TrialInternational journal of clinical oncology2017

Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

Takako Inoue et al.PubMed ↗Publisher ↗

No numbers read from the abstract.